Annual Accounts Receivable
$36.25 M
+$14.10 M+63.63%
December 31, 2023
Summary
- As of March 9, 2025, OPRX annual accounts receivable is $36.25 million, with the most recent change of +$14.10 million (+63.63%) on December 31, 2023.
- During the last 3 years, OPRX annual accounts receivable has risen by +$18.37 million (+102.69%).
- OPRX annual accounts receivable is now at all-time high.
Performance
OPRX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$26.33 M
+$1.81 M+7.37%
September 30, 2024
Summary
- As of March 9, 2025, OPRX quarterly accounts receivable is $26.33 million, with the most recent change of +$1.81 million (+7.37%) on September 30, 2024.
- Over the past year, OPRX quarterly accounts receivable has increased by +$5.49 million (+26.34%).
- OPRX quarterly accounts receivable is now -27.38% below its all-time high of $36.25 million, reached on December 31, 2023.
Performance
OPRX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
OPRX Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +63.6% | +26.3% |
| 3 y3 years | +102.7% | +6.2% |
| 5 y5 years | +461.4% | +254.9% |
OPRX Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +63.6% | -27.4% | +47.8% |
| 5 y | 5-year | at high | +388.7% | -27.4% | +254.9% |
| alltime | all time | at high | -100.0% | -27.4% | >+9999.0% |
OptimizeRx Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $26.33 M(+7.4%) |
| Jun 2024 | - | $24.52 M(-17.6%) |
| Mar 2024 | - | $29.75 M(-17.9%) |
| Dec 2023 | $36.25 M(+63.6%) | $36.25 M(+74.0%) |
| Sep 2023 | - | $20.84 M(+14.0%) |
| Jun 2023 | - | $18.28 M(+0.6%) |
| Mar 2023 | - | $18.16 M(-18.0%) |
| Dec 2022 | $22.16 M(-10.7%) | $22.16 M(+24.4%) |
| Sep 2022 | - | $17.81 M(-4.9%) |
| Jun 2022 | - | $18.73 M(-2.1%) |
| Mar 2022 | - | $19.14 M(-22.8%) |
| Dec 2021 | $24.80 M(+38.7%) | $24.80 M(+19.5%) |
| Sep 2021 | - | $20.75 M(+15.7%) |
| Jun 2021 | - | $17.93 M(+21.7%) |
| Mar 2021 | - | $14.74 M(-17.6%) |
| Dec 2020 | $17.89 M(+141.1%) | $17.89 M(+34.2%) |
| Sep 2020 | - | $13.33 M(+23.4%) |
| Jun 2020 | - | $10.81 M(+19.2%) |
| Mar 2020 | - | $9.06 M(+22.2%) |
| Dec 2019 | $7.42 M(+14.9%) | $7.42 M(+3.6%) |
| Sep 2019 | - | $7.16 M(-3.6%) |
| Jun 2019 | - | $7.42 M(+51.4%) |
| Mar 2019 | - | $4.90 M(-24.1%) |
| Dec 2018 | $6.46 M(+88.2%) | $6.46 M(+25.0%) |
| Sep 2018 | - | $5.17 M(-6.3%) |
| Jun 2018 | - | $5.51 M(+43.3%) |
| Mar 2018 | - | $3.85 M(+12.1%) |
| Dec 2017 | $3.43 M(+12.1%) | $3.43 M(+26.8%) |
| Sep 2017 | - | $2.70 M(+11.7%) |
| Jun 2017 | - | $2.42 M(-13.7%) |
| Mar 2017 | - | $2.81 M(-8.3%) |
| Dec 2016 | $3.06 M | $3.06 M(+31.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2016 | - | $2.32 M(+10.2%) |
| Jun 2016 | - | $2.11 M(-9.9%) |
| Mar 2016 | - | $2.34 M(-17.8%) |
| Dec 2015 | $2.85 M(+35.6%) | $2.85 M(+3.9%) |
| Sep 2015 | - | $2.74 M(+42.8%) |
| Jun 2015 | - | $1.92 M(+5.8%) |
| Mar 2015 | - | $1.81 M(-13.7%) |
| Dec 2014 | $2.10 M(+38.9%) | $2.10 M(+30.1%) |
| Sep 2014 | - | $1.61 M(+27.7%) |
| Jun 2014 | - | $1.26 M(+13.8%) |
| Mar 2014 | - | $1.11 M(-26.5%) |
| Dec 2013 | $1.51 M(+145.1%) | $1.51 M(+31.6%) |
| Sep 2013 | - | $1.15 M(+22.3%) |
| Jun 2013 | - | $939.70 K(+42.2%) |
| Mar 2013 | - | $660.70 K(+7.1%) |
| Dec 2012 | $616.80 K(+30.7%) | $616.80 K(-4.2%) |
| Sep 2012 | - | $643.60 K(+22.4%) |
| Jun 2012 | - | $526.00 K(+351.5%) |
| Mar 2012 | - | $116.50 K(-75.3%) |
| Dec 2011 | $471.90 K(+108.8%) | $471.90 K(+287.8%) |
| Sep 2011 | - | $121.70 K(-13.1%) |
| Jun 2011 | - | $140.10 K(-58.7%) |
| Mar 2011 | - | $338.90 K(+50.0%) |
| Dec 2010 | $226.00 K(+1458.6%) | $226.00 K(+533.1%) |
| Sep 2010 | - | $35.70 K(+5000.0%) |
| Jun 2010 | - | $700.00(0.0%) |
| Mar 2010 | - | $700.00(-95.2%) |
| Dec 2009 | $14.50 K(+1015.4%) | $14.50 K(+195.9%) |
| Sep 2009 | - | $4900.00(+188.2%) |
| Jun 2009 | - | $1700.00(+30.8%) |
| Dec 2008 | $1300.00(>+9900.0%) | $1300.00 |
| Dec 2007 | $0.00 | - |
FAQ
- What is OptimizeRx annual accounts receivable?
- What is the all time high annual accounts receivable for OptimizeRx?
- What is OptimizeRx annual accounts receivable year-on-year change?
- What is OptimizeRx quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for OptimizeRx?
- What is OptimizeRx quarterly accounts receivable year-on-year change?
What is OptimizeRx annual accounts receivable?
The current annual accounts receivable of OPRX is $36.25 M
What is the all time high annual accounts receivable for OptimizeRx?
OptimizeRx all-time high annual accounts receivable is $36.25 M
What is OptimizeRx annual accounts receivable year-on-year change?
Over the past year, OPRX annual accounts receivable has changed by +$14.10 M (+63.63%)
What is OptimizeRx quarterly accounts receivable?
The current quarterly accounts receivable of OPRX is $26.33 M
What is the all time high quarterly accounts receivable for OptimizeRx?
OptimizeRx all-time high quarterly accounts receivable is $36.25 M
What is OptimizeRx quarterly accounts receivable year-on-year change?
Over the past year, OPRX quarterly accounts receivable has changed by +$5.49 M (+26.34%)